Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.
Masahiro MoriTakashi OhashiYasuhiro OnizukaKatsutoshi HiramatsuMasakazu HaseJang YunAndré MattaShinichi ToriiPublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
Dimethyl fumarate demonstrated sustained efficacy and acceptable tolerability in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis for 72 weeks.